Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

PET Cell Tracking Using <sup>18</sup>F-FLT is Not Limited by Local Reuptake of Free Radiotracer

MacAskill MG., Tavares AS., Wu J., Lucatelli C., Mountford JC., Baker AH.

Laboratory Study on Peripheral Artery Disease, published in Sci Rep (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Sci Rep (2017)
Reported sample size
—
Source database
Europe PMC
PMID
28287126
PMCID
PMC5347009
DOI
10.1038/srep44233
Citations
11

Abstract (original English)

Assessing the retention of cell therapies following implantation is vital and often achieved by labelling cells with 2'-[ 18 F]-fluoro-2'-deoxy-D-glucose ( 18 F-FDG). However, this approach is limited by local retention of cell-effluxed radiotracer. Here, in a preclinical model of critical limb ischemia, we assessed a novel method of cell tracking using 3'-deoxy-3'-L-[ 18 F]-fluorothymidine ( 18 F-FLT); a clinically available radiotracer which we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimation of cell retention. Human endothelial cells (HUVECs) were incubated with 18 F-FDG or 18 F-FLT and cell characteristics were evaluated. Dynamic positron emission tomography (PET) images were acquired post-injection of free 18 F-FDG/ 18 F-FLT or 18 F-FDG/ 18 F-FLT-labelled HUVECs, following the surgical induction of mouse hind-limb ischemia. In vitro, radiotracer incorporation and efflux was similar with no effect on cell viability, function or proliferation under optimised conditions (5 MBq/mL, 60 min). Injection of free radiotracer demonstrated a faster clearance of 18 F-FLT from the injection site vs. 18 F-FDG (p ≤ 0.001), indicating local cellular uptake. Using 18 F-FLT-labelling, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 ± 3.2%. PET cell tracking using 18 F-FLT labelling is an improved a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansRadioactive TracersDideoxynucleosidesCell TrackingHuman Umbilical Vein Endothelial CellsPositron Emission Tomography Computed Tomography

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research